News
Karolinska Institutet, Cellply Partner to Improve Knowledge of NK Cell Therapies in Multiple Myeloma
Researchers will use Cellply's VivaCyte platform to conduct single-cell analyses of NK cells and evaluate their ability to treat the bone marrow cancer.
The firm will test the drug with immune checkpoint inhibitors in NSCLC patients with low PD-L1 expression and KEAP1 and/or STK11 mutations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback